UTILITY OF HBME1 IMMUNOSTAIN IN DIFFERENTIATING REACTIVE MESOTHELIAL CELLS LESIONS FROM MALIGNANT EPITHELIAL CELLS LESIONS IN SEROUS EFFUSIONS
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i6.47279Keywords:
Human Battifora Mesothelial Epitope- 1, Cellblock, Effusion, Reactive mesothelial cells, Malignant epithelial cellsAbstract
Objective: Parietal and the visceral layers of the mesothelium are separated by a thin layer of lubricating fluid and are made up of a single layer of flat cells. The three body cavities pleura, peritoneum, and pericardium are lined by mesothelium. The collection of fluid inside these cavities is called an effusion and may be due to a variety of inflammatory, infective, and neoplastic causes and often causes reactive mesothelial cells hyperplasia that sometimes is very hard to differentiate from malignant epithelial cells in cytopathological examinations of these fluids.
Methods: We studied the utility of the Human Battifora Mesothelial Epitope-1 (HBME1) immunostain to differentiate these conditions. All the fluids from various effusions collected at the department of pathology, at a tertiary care institute in Lucknow were included in the study. Detailed history, examination findings, blood investigations, imaging findings, and histopathology reports were also noted. Fluids that showed reactive mesothelial hyperplasia and/or malignant epithelial cells on microscopic examination were further analyzed by the application of HBME1 on the cell block.
Results: A total of 50 fluids were studied finally including 30 cases from the positive malignant cells group and 20 cases from the reactive mesothelial cells group. Out of 30 cases included in the malignant cells group, 16 cases (53.33%) were immunoreactive for HBME1, and out of the 20 cases included in the reactive mesothelial cell group, 18 cases (90%) showed immunoreactivity for HBME1.
Conclusion: Observing this we can conclude that HBME1 immunoreactivity was significantly associated with the presence of reactive mesothelial cells compared to the malignant cells group.
Downloads
References
Winters NI, Bader DM. Development of the serosal mesothelium. J Dev Biol 2013;1:64-81. doi: 10.3390/jdb1020064
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018;52:1800349. doi: 10.1183/13993003.00349- 2018, PMID 30054348
Beaudoin S, Gonzalez AV. Evaluation of the patient with pleural effusion. CMAJ 2018;190:E291-5. doi: 10.1503/cmaj.170420, PMID 29530870
Mohanty SK, Dey P. Serous effusions: Diagnosis of malignancy beyond cytomorphology. An analytic review. Postgrad Med J 2003;79:569-74. doi: 10.1136/pmj.79.936.569, PMID 14612599
Murugan P, Siddaraju N, Habeebullah S, Basu D. Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: A combination panel-based approach with a brief review of the literature. Indian J Pathol Microbiol 2009;52:175-81. doi: 10.4103/0377-4929.48910, PMID 19332905
Yeh CJ, Chuang WY, Chou HH, Jung SM, Hsueh S. Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS 2008;116:1016-9. doi: 10.1111/j.1600-0463.2008.01084.x, PMID 19133002
Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwaller B. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 2009;174:2324-36. doi:10.2353/ajpath.2009.080352, PMID 19435792
Donna A, Betta PG, Chiodera P, Bellingeri D, Libener R, Zorzi F, et al. Newly marketed tissue markers for malignant mesothelioma: Immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 1997;28:929-37. doi: 10.1016/s0046-8177(97)90008-3, PMID 9269829
Rahmani A, Dehghani MZ, Afshar NM, Heidarian H, Tahririan R. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid. Indian J Pathol Microbiol 2011;54:460-3. doi: 10.4103/0377-4929.85075, PMID 21934203
Afshar NM, Behnaz S, Emami AM, Hashemi BM, Masumeh R, Ashkan Z. The diagnostic value of p53 and desmin in the differentiation between reactive mesothelial cells and metastatic adeno-carcinoma in pleural effusion. Biomed J Sci Tech Res 2019;18:13331-6. doi: 10.26717/BJSTR.2019.18.003107
Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-5. doi: 10.1002/dc.20203, PMID 15690338
Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1997;8:328-35. doi: 10.1111/j.1365-2303.1997.tb00557.x, PMID 9313985
Mocanu L, Cîmpean AM, Raica M. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions. Rom J Morphol Embryol 2006;47:351-5. PMID 17392981
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr Sonal Raut, Dr Mustafa Ali, Dr Reetesh Kumar Gujar, Dr Fatima Bhopalwala
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
